Shackelford Pharma

We have identified at least 14 indications to date, which are now being used to focus our efforts on three distinct parallel and highly encouraging tracks to bring Shackelford Pharma cannabinoid medicines to market:Prescription: pharmaceutical products (drug identification number) that will be pursued for full regulatory approval. High unmet needs such as rare diseases and “Orphan drugs” — which government’s have made a public health priority for rare disease that don’t always get the industry research and development needed to produce these drugs for people in need. Our R&D and Dr. Shackelford's clinical experience indicates cannabinoids will be a highly valuable addition to the orphan drug spectrum.